AstraZeneca this week became the second company in recent weeks to announce it will cap the out-of-pocket costs that patients pay for its inhalers at $35. The cap is effective June 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort, Breztri Aerosphere, and Airsupra. The cap will be applicable for patients who are uninsured or underinsured.
